Pelthos Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.8M | $0 | — | — | — |
| Cost of revenue | $4.0M | $0 | — | — | — |
| Selling, general & administrative | $42.5M | $6.4M | — | — | — |
| Research and development | $1.2M | $1.2M | $2.6M | $391,730 | — |
| Operating expenses | — | $7.6M | $6.9M | $2.3M | — |
| Operating income | -$32.4M | -$7.6M | -$6.9M | -$2.3M | — |
| Interest expense | $3.0M | $786,000 | — | — | — |
| Pretax income | -$50.7M | -$8.0M | -$7.4M | -$2.5M | — |
| Income tax expense | -$7.4M | $0 | — | — | — |
| Net income | -$43.3M | -$8.0M | -$7.4M | -$2.5M | — |
| Balance Sheet | |||||
| Cash and equivalents | $18.0M | $513,000 | $100,000 | $100,000 | — |
| Current assets | $53.4M | $1.4M | $96,391 | $55,074 | — |
| Total assets | $130.4M | $1.4M | $96,391 | $55,074 | — |
| Current liabilities | $26.0M | $4.1M | $6.5M | $3.8M | — |
| Total liabilities | $91.5M | $4.1M | $6.5M | $3.8M | — |
| Stockholders' equity | $38.9M | -$2.7M | -$6.4M | -$3.7M | -$3.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$22.6M | -$5.8M | -$981,031 | -$1.6M | — |
| Depreciation and amortization | $729,000 | $0 | — | — | — |
| Stock-based compensation | $5.5M | $1.8M | $1.7M | $110,146 | — |
| Capital expenditure | $99,000 | $0 | — | — | — |
| Free cash flow | -$22.7M | -$5.8M | — | — | — |
| Share repurchases | $0 | $75,000 | — | — | — |
| Impairments | $285,000 | $0 | — | — | — |
Shares outstanding 3.5M · Free float 78.6%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.